Status:

RECRUITING

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Lead Sponsor:

Apellis Pharmaceuticals, Inc.

Conditions:

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Hemoglobinuria

Eligibility:

All Genders

12-17 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescen...

Detailed Description

This is an open-label study to evaluate pegcetacoplan in people with PNH who are 12-17 years old. The study will consist of a 4-week screening period followed by a 16-week treatment period. Participan...

Eligibility Criteria

Inclusion

  • Are 12-17 years old at the time of screening
  • Weigh at least 20 kg (approx. 44 lbs)
  • Have the diagnosis of PNH, confirmed by high-sensitivity flow cytometry (granulocyte or monocyte clone \>10%)
  • EITHER:
  • Not being treated with an approved complement inhibitor (eculizumab or ravulizumab) prior to start of pegcetacoplan dosing, AND have hemolytic anemia. Hemolytic anemia is defined as hemoglobin (Hb) less than the lower limit of normal (Hb \< LLN) and LDH \>1.5 times the upper limit of normal (ULN); OR
  • Currently receiving treatment with an approved complement inhibitor (eculizumab or ravulizumab) AND have evidence of ongoing anemia. Ongoing anemia is defined as Hb \< LLN and ARC \> ULN
  • Have a platelet count \>75,000/mm3 and an absolute neutrophil count \>1000/mm3

Exclusion

  • Are an adult, 18 years of age or older, with PNH
  • Known or suspected hereditary fructose intolerance (HFI)
  • History of hereditary complement deficiency, bone marrow transplant, or meningococcal disease (meningitis, bacteremia or septicemia)
  • Females who are pregnant or breastfeeding

Key Trial Info

Start Date :

February 4 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2028

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT04901936

Start Date

February 4 2021

End Date

December 1 2028

Last Update

June 11 2025

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Children's Hospital of Atlanta

Atlanta, Georgia, United States, 30329

2

Motol University Hospital

Prague, Czechia, 150 06

3

Robert-Debré Hospital Paris

Paris, France, 75009

4

Hospital Ampang

Ampang, Malaysia, 68000